These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 36879635)

  • 1. [Clinical and epidemiological features of COVID-19-related deaths in Tunisia before the emergence of VOCs (March 2020-February 2021)].
    Dhaouadi S; Hechaichi A; Letaief H; Safer M; Mziou E; Talmoudi K; Borgi C; Chebbi H; Somrani N; Ali MB; Yahyaoui S; Mseddi A; Chahed MK; Ferjani M; Alaya NB
    Pan Afr Med J; 2022; 43():172. PubMed ID: 36879635
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Baseline Seroprevalence of SARS-CoV-2 Specific Antibodies in Hot Spot Areas of Great Tunis, up to 3 Months Post Disease Onset in Tunisia.
    Dhaouadi S; Letaief H; Hechaichi A; Safer M; Moussa R; Bouhali R; Letaief F; Abdelkader L; Ben Salah H; El Mili N; Hammami M; Talmoudi K; Souteyrand Y; Nabeth P; Kouni Chahed M; Bouafif Ép Ben Alaya N
    Epidemiologia (Basel); 2023 Jun; 4(2):188-201. PubMed ID: 37367185
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Factors associated with the spatial heterogeneity of the first wave of COVID-19 in France: a nationwide geo-epidemiological study.
    Gaudart J; Landier J; Huiart L; Legendre E; Lehot L; Bendiane MK; Chiche L; Petitjean A; Mosnier E; Kirakoya-Samadoulougou F; Demongeot J; Piarroux R; Rebaudet S
    Lancet Public Health; 2021 Apr; 6(4):e222-e231. PubMed ID: 33556327
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Comparative study of patients hospitalized for SARS-CoV-2 infection in two consecutive waves in Tunisia].
    Rachdi R; Hannachi S; Zribi S; Ayed O; Abid R; Moatemri Z; Mhamdi S; Dabboussi S; Gharsallah H; Sellami W; Sammoud W; Massoudi H; Lamine K; Djebbi O; Hammami R; Ben Moussa M; Bellaaj R; Battikh R; Rachdi MR; Ferjani M
    Med Trop Sante Int; 2022 Sep; 2(3):. PubMed ID: 36284562
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characteristics of cases and deaths arising from SARS-CoV-2 infection in Zambia: March 2020 to April 2021.
    Chanda SL; Tembo E; Sinyange N; Kayeyi N; Musonda K; Chewe O; Kasonde M; Kapona O; Ngomah A; Hamukale A; Zulu PM; Kapina M
    Pan Afr Med J; 2023; 45():155. PubMed ID: 37869234
    [TBL] [Abstract][Full Text] [Related]  

  • 6. COVID-19, Australia: Epidemiology Report 19 (Fortnightly reporting period ending 21 June 2020).
    COVID-19 National Incident Room Surveillance Team
    Commun Dis Intell (2018); 2020 Jun; 44():. PubMed ID: 32600222
    [TBL] [Abstract][Full Text] [Related]  

  • 7. COVID-19 deaths in children and young people in England, March 2020 to December 2021: An active prospective national surveillance study.
    Bertran M; Amin-Chowdhury Z; Davies HG; Allen H; Clare T; Davison C; Sinnathamby M; Seghezzo G; Kall M; Williams H; Gent N; Ramsay ME; Ladhani SN; Oligbu G
    PLoS Med; 2022 Nov; 19(11):e1004118. PubMed ID: 36346784
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Estimating the infection-fatality risk of SARS-CoV-2 in New York City during the spring 2020 pandemic wave: a model-based analysis.
    Yang W; Kandula S; Huynh M; Greene SK; Van Wye G; Li W; Chan HT; McGibbon E; Yeung A; Olson D; Fine A; Shaman J
    Lancet Infect Dis; 2021 Feb; 21(2):203-212. PubMed ID: 33091374
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial.
    Akova M; Unal S
    Trials; 2021 Apr; 22(1):276. PubMed ID: 33849629
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Studying SARS-CoV-2 vaccine hesitancy among health professionals in Tunisia.
    Zammit N; Gueder AE; Brahem A; Ayouni I; Ghammam R; Fredj SB; Sridi C; Chouchene A; Kalboussi H; Maalel OE; Chatti S; Maatoug J; Ghannem H; Mrizak N
    BMC Health Serv Res; 2022 Apr; 22(1):489. PubMed ID: 35413911
    [TBL] [Abstract][Full Text] [Related]  

  • 11. COVID-19, Australia: Epidemiology Report 18 (Fortnightly reporting period ending 7 June 2020).
    COVID-19 National Incident Room Surveillance Team
    Commun Dis Intell (2018); 2020 Jun; 44():. PubMed ID: 32552623
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [SENTIERI - Epidemiological Study of Residents in National Priority Contaminated Sites. Sixth Report].
    Zona A; Fazzo L; Benedetti M; Bruno C; Vecchi S; Pasetto R; Minichilli F; De Santis M; Nannavecchia AM; Di Fonzo D; Contiero P; Ricci P; Bisceglia L; Manno V; Minelli G; Santoro M; Gorini F; Ancona C; Scondotto S; Soggiu ME; Scaini F; Beccaloni E; Marsili D; Villa MF; Maifredi G; Magoni M; Iavarone I;
    Epidemiol Prev; 2023; 47(1-2 Suppl 1):1-286. PubMed ID: 36825373
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Whole genome sequencing and phylogenetic analysis of six SARS-CoV-2 strains isolated during COVID-19 pandemic in Tunisia, North Africa.
    Fares W; Chouikha A; Ghedira K; Gdoura M; Rezig D; Boubaker SH; Dhifallah IB; Touzi H; Hammami W; Meddeb Z; Sadraoui A; Hogga N; Abouda I; Kwasiborski A; Hourdel V; Mikaty G; Caro V; Manuguerra JC; Alaya NB; Triki H
    BMC Genomics; 2021 Jul; 22(1):540. PubMed ID: 34261445
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Case-fatality rates of SARS-CoV-2 infection according to Autonomous Communities during the second epidemic wave in Spain].
    Ruiz-García A; Vitelli-Storelli F; Serrano-Cumplido A; Segura-Fragoso A; Calderón-Montero A; Mico-Pérez RM; Barquilla-García A; Morán-Bayón Á; Linares M; Olmo-Quintana V; Martín-Sánchez V;
    Semergen; 2022; 48(4):252-262. PubMed ID: 35437189
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Duration of vaccine effectiveness against SARS-CoV-2 infection, hospitalisation, and death in residents and staff of long-term care facilities in England (VIVALDI): a prospective cohort study.
    Shrotri M; Krutikov M; Nacer-Laidi H; Azmi B; Palmer T; Giddings R; Fuller C; Irwin-Singer A; Baynton V; Tut G; Moss P; Hayward A; Copas A; Shallcross L
    Lancet Healthy Longev; 2022 Jul; 3(7):e470-e480. PubMed ID: 35813279
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risk factors for severe Covid-19 breakthrough infections: an observational longitudinal study.
    Ben Fredj S; Ghammem R; Zammit N; Maatouk A; Haddad N; Haddad N; Kachroudi M; Rebai S; Laadhari H; Ghodhbani MM; Maatoug J; Ghannem H
    BMC Infect Dis; 2022 Nov; 22(1):894. PubMed ID: 36443699
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inland expansion of COVID-19 in Western Bahia: epidemiological profile and spatial analysis of deaths and confirmed cases.
    Gomes DR; Souza RC; Oliveira UR; Mattos MP; Aleluia ÍRS; Mapeli AM
    Cien Saude Colet; 2021 Oct; 26(10):4665-4680. PubMed ID: 34730653
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Epidemiology and public health response in early phase of COVID-19 pandemic, Veneto Region, Italy, 21 February to 2 April 2020.
    Russo F; Pitter G; Da Re F; Tonon M; Avossa F; Bellio S; Fedeli U; Gubian L; Monetti D; Saia M; Zanella F; Zorzi M; Narne E; Mantoan D
    Euro Surveill; 2020 Nov; 25(47):. PubMed ID: 33243356
    [TBL] [Abstract][Full Text] [Related]  

  • 19. SARS-CoV-2 infection fatality rate after the first epidemic wave in Mexico.
    Torres-Ibarra L; Basto-Abreu A; Carnalla M; Torres-Alvarez R; Reyes-Sanchez F; Hernández-Ávila JE; Palacio-Mejia LS; Alpuche-Aranda C; Shamah-Levy T; Rivera JA; Barrientos-Gutierrez T
    Int J Epidemiol; 2022 May; 51(2):429-439. PubMed ID: 35157072
    [TBL] [Abstract][Full Text] [Related]  

  • 20. COVID-19, Australia: Epidemiology Report 17 (Fortnightly reporting period ending 24 May 2020).
    COVID-19 National Incident Room Surveillance Team
    Commun Dis Intell (2018); 2020 Jun; 44():. PubMed ID: 32517645
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.